A Combination of Sorafenib, Oxaliplatin and Capecitabine as Neoadjuvant Therapy for Patients with Locally Advanced Hepatocelullar Carcinoma: A Phase II Study
Grant Data
Project Title
A Combination of Sorafenib, Oxaliplatin and Capecitabine as Neoadjuvant Therapy for Patients with Locally Advanced Hepatocelullar Carcinoma: A Phase II Study
Principal Investigator
Dr Yau, Thomas Chung Cheung
(Principal Investigator (PI))
Co-Investigator(s)
Professor Cheung Tan To
(Co-Investigator)
Duration
24
Start Date
2016-12-01
Amount
1196896
Conference Title
A Combination of Sorafenib, Oxaliplatin and Capecitabine as Neoadjuvant Therapy for Patients with Locally Advanced Hepatocelullar Carcinoma: A Phase II Study
Presentation Title
Keywords
capecitabine, hepatocellular carcinoma, neoadjuvant, oxaliplatin, sorafenib, unresectable
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
03143956
Grant Type
Health and Medical Research Fund - Full Grant
Funding Year
2015
Status
Completed
Objectives
We propose to assess the efficacy and safety of using the combination of sorafenib together with oxaliplatin and capecitabine (SECOX) regimen as neoadjuvant therapy to downstage locally advanced HCC patients for potential curative hepatectomy.